PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Organic Payment Gateways, a leading provider of specialized payment solutions, proudly announces the launch of its easily integrated payment gateway and merchant account program. This program is ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

The luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients ...

Pursuing dangerous Medicaid block grant schemes and allowing flagrant violations of unequivocal state laws looks like ...

The Trump administration has promised that addressing childhood obesity will be a key part of its “Make America Healthy Again ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.